Gastroenteropancreatic Neuroendocrine Tumours
Also known as: Gastro-entero-pancreatic Neuroendocrine Tumor / Gastro-entero Pancreatic Neuroendocrine Tumors / Gastro Entero Pancreatic Neuroendocrine Tumors / Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) / Neuroendocrine Gastroenteropancreatic Tumour / Gastro-entero-pancreatic Neuroendocrine Tumors / GEP-NET / Gastro-enteropancreatic Neuroendocrine Tumor / Gastro-Entero-Pancreatic Tumors (GEPs) / Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) / Neuroendocrine Tumors,Gastroenteropancreatic / Gastroenteral-Pancreatic Neuroendocrine Tumors / Gastroenteropancreatic Neuroendocrine Tumor / Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) / Gastroenteropancreatic Neuroendocrine Tumors / Gastroenteropancreatic Neuroendocrine Tumor Disease / Gep Net / Gastroenteropancreatic neuroendocrine tumour disease
Drug | Drug Name | Drug Description |
---|---|---|
DB13985 | Lutetium Lu 177 dotatate | A radiolabeled somatostatin analog used to treat somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors. |
DB12602 | Pentetreotide | A somatostatin receptor inhibitor, available in a kit with Indium-111, used as a contrast agent in the visualization of somatostatin receptor-positive neuroendocrine tumours. |